Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast CancerJosé Baselga, Frederico Costa, Hélio Pinczowski et al.|Journal of Clinical Oncology|2012Cited by 163
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88